Changes of Serum HER2 Status during Clinical Course of Metastatic Breast Cancer Patients
Background: Serum HER2 testing allows the determination of the real-time HER2 status of breast cancer patients. The aim of this investigation was to study (i) whether changes of serum HER2 status occur during the clinical course of breast cancer and (ii) to evaluate the prognostic significance of se...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2004-11, Vol.24 (6), p.4205-4210 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4210 |
|---|---|
| container_issue | 6 |
| container_start_page | 4205 |
| container_title | Anticancer research |
| container_volume | 24 |
| creator | FEHM, T JÄGER, W KRAEMER, S SOHN, C SOLOMAYER-MEYBERG, G SOLOMAYER, Ef KUREK, R WALLWIENER, D GEBAUER, G |
| description | Background: Serum HER2 testing allows the determination of the real-time HER2 status of breast cancer patients. The aim of
this investigation was to study (i) whether changes of serum HER2 status occur during the clinical course of breast cancer
and (ii) to evaluate the prognostic significance of serum HER2 status, at the time of first diagnosis of primary breast cancer
and at the onset of metastatic disease, for survival after relapse (SAR). Materials and Methods: HER2 serum levels were retrospectively
measured in 152 breast cancer patients at the time of first diagnosis of breast cancer and at the onset of metastatic disease
by enzyme immunoassay. Results: Twenty-seven out of 152 (18%) patients had elevated HER2 serum levels at the time of first
diagnosis of breast cancer. In contrast, 56 out of 152 (37%) patients showed elevated serum HER2 levels when metastases were
diagnosed. A change of serum HER2 status during clinical course was observed in 43 out of 152 (28%) patients. Serum HER2 status
at the time of first diagnosis of breast cancer had no impact on survival after relapse (SAR) (p=0.4). However, the median
SAR for serum HER2-positive patients at the onset of metastatic disease was significantly shorter (8 months, 95% CI: 3-12)
compared to patients serum HER2-negative at this time (18 months, 95% CI: 14-22) (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67251797</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67251797</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-6782081312a438c4da74cedf7aea04c2c654e9786d999b099c79f98dd268e53c3</originalsourceid><addsrcrecordid>eNpF0F1LwzAUBuAgipvTvyC50btCms_mUst0wkRxCt6FLD1dI203kxbx3xtxsqtzODy8cN4jNM2VzjMlGDlGU0IFyRQhYoLOYvwgREpdsFM0yYVimko-Re9lY_sNRLyt8QrC2OHF_IXi1WCHMeJqDL7f4LL1vXe2xeV2DBF-7SMMNibkHb4NkFZc2t5BwM_pBv0Qz9FJbdsIF_s5Q29389dykS2f7h_Km2XWUKmHTKqCkiJnObWcFY5XVnEHVa0sWMIddVJw0KqQldZ6TbR2Ste6qCoqCxDMsRm6_svdhe3nCHEwnY8O2tb2sB2jkYqK1IlK8HIPx3UHldkF39nwbf67SOBqD2xMz9YhPeTjwUkhci3owTV-03z5ACZ2tm1TLDM2UG6k4ZQI9gNwXnQ5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67251797</pqid></control><display><type>article</type><title>Changes of Serum HER2 Status during Clinical Course of Metastatic Breast Cancer Patients</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>FEHM, T ; JÄGER, W ; KRAEMER, S ; SOHN, C ; SOLOMAYER-MEYBERG, G ; SOLOMAYER, Ef ; KUREK, R ; WALLWIENER, D ; GEBAUER, G</creator><creatorcontrib>FEHM, T ; JÄGER, W ; KRAEMER, S ; SOHN, C ; SOLOMAYER-MEYBERG, G ; SOLOMAYER, Ef ; KUREK, R ; WALLWIENER, D ; GEBAUER, G</creatorcontrib><description>Background: Serum HER2 testing allows the determination of the real-time HER2 status of breast cancer patients. The aim of
this investigation was to study (i) whether changes of serum HER2 status occur during the clinical course of breast cancer
and (ii) to evaluate the prognostic significance of serum HER2 status, at the time of first diagnosis of primary breast cancer
and at the onset of metastatic disease, for survival after relapse (SAR). Materials and Methods: HER2 serum levels were retrospectively
measured in 152 breast cancer patients at the time of first diagnosis of breast cancer and at the onset of metastatic disease
by enzyme immunoassay. Results: Twenty-seven out of 152 (18%) patients had elevated HER2 serum levels at the time of first
diagnosis of breast cancer. In contrast, 56 out of 152 (37%) patients showed elevated serum HER2 levels when metastases were
diagnosed. A change of serum HER2 status during clinical course was observed in 43 out of 152 (28%) patients. Serum HER2 status
at the time of first diagnosis of breast cancer had no impact on survival after relapse (SAR) (p=0.4). However, the median
SAR for serum HER2-positive patients at the onset of metastatic disease was significantly shorter (8 months, 95% CI: 3-12)
compared to patients serum HER2-negative at this time (18 months, 95% CI: 14-22) (p<0.01). Conclusion: Serum HER2 status can
change during the course of disease. Therefore, the serum HER2 status should be re-evaluated at the time of diagnosis of metastatic
disease to optimize treatment decisions.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 15739264</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Biological and medical sciences ; Breast Neoplasms - blood ; Breast Neoplasms - pathology ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Mammary gland diseases ; Medical sciences ; Neoplasm Metastasis ; Receptor, ErbB-2 - blood ; Retrospective Studies ; Tumors</subject><ispartof>Anticancer research, 2004-11, Vol.24 (6), p.4205-4210</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16551952$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15739264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FEHM, T</creatorcontrib><creatorcontrib>JÄGER, W</creatorcontrib><creatorcontrib>KRAEMER, S</creatorcontrib><creatorcontrib>SOHN, C</creatorcontrib><creatorcontrib>SOLOMAYER-MEYBERG, G</creatorcontrib><creatorcontrib>SOLOMAYER, Ef</creatorcontrib><creatorcontrib>KUREK, R</creatorcontrib><creatorcontrib>WALLWIENER, D</creatorcontrib><creatorcontrib>GEBAUER, G</creatorcontrib><title>Changes of Serum HER2 Status during Clinical Course of Metastatic Breast Cancer Patients</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: Serum HER2 testing allows the determination of the real-time HER2 status of breast cancer patients. The aim of
this investigation was to study (i) whether changes of serum HER2 status occur during the clinical course of breast cancer
and (ii) to evaluate the prognostic significance of serum HER2 status, at the time of first diagnosis of primary breast cancer
and at the onset of metastatic disease, for survival after relapse (SAR). Materials and Methods: HER2 serum levels were retrospectively
measured in 152 breast cancer patients at the time of first diagnosis of breast cancer and at the onset of metastatic disease
by enzyme immunoassay. Results: Twenty-seven out of 152 (18%) patients had elevated HER2 serum levels at the time of first
diagnosis of breast cancer. In contrast, 56 out of 152 (37%) patients showed elevated serum HER2 levels when metastases were
diagnosed. A change of serum HER2 status during clinical course was observed in 43 out of 152 (28%) patients. Serum HER2 status
at the time of first diagnosis of breast cancer had no impact on survival after relapse (SAR) (p=0.4). However, the median
SAR for serum HER2-positive patients at the onset of metastatic disease was significantly shorter (8 months, 95% CI: 3-12)
compared to patients serum HER2-negative at this time (18 months, 95% CI: 14-22) (p<0.01). Conclusion: Serum HER2 status can
change during the course of disease. Therefore, the serum HER2 status should be re-evaluated at the time of diagnosis of metastatic
disease to optimize treatment decisions.</description><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - pathology</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Neoplasm Metastasis</subject><subject>Receptor, ErbB-2 - blood</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0F1LwzAUBuAgipvTvyC50btCms_mUst0wkRxCt6FLD1dI203kxbx3xtxsqtzODy8cN4jNM2VzjMlGDlGU0IFyRQhYoLOYvwgREpdsFM0yYVimko-Re9lY_sNRLyt8QrC2OHF_IXi1WCHMeJqDL7f4LL1vXe2xeV2DBF-7SMMNibkHb4NkFZc2t5BwM_pBv0Qz9FJbdsIF_s5Q29389dykS2f7h_Km2XWUKmHTKqCkiJnObWcFY5XVnEHVa0sWMIddVJw0KqQldZ6TbR2Ste6qCoqCxDMsRm6_svdhe3nCHEwnY8O2tb2sB2jkYqK1IlK8HIPx3UHldkF39nwbf67SOBqD2xMz9YhPeTjwUkhci3owTV-03z5ACZ2tm1TLDM2UG6k4ZQI9gNwXnQ5</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>FEHM, T</creator><creator>JÄGER, W</creator><creator>KRAEMER, S</creator><creator>SOHN, C</creator><creator>SOLOMAYER-MEYBERG, G</creator><creator>SOLOMAYER, Ef</creator><creator>KUREK, R</creator><creator>WALLWIENER, D</creator><creator>GEBAUER, G</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Changes of Serum HER2 Status during Clinical Course of Metastatic Breast Cancer Patients</title><author>FEHM, T ; JÄGER, W ; KRAEMER, S ; SOHN, C ; SOLOMAYER-MEYBERG, G ; SOLOMAYER, Ef ; KUREK, R ; WALLWIENER, D ; GEBAUER, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-6782081312a438c4da74cedf7aea04c2c654e9786d999b099c79f98dd268e53c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - pathology</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Neoplasm Metastasis</topic><topic>Receptor, ErbB-2 - blood</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FEHM, T</creatorcontrib><creatorcontrib>JÄGER, W</creatorcontrib><creatorcontrib>KRAEMER, S</creatorcontrib><creatorcontrib>SOHN, C</creatorcontrib><creatorcontrib>SOLOMAYER-MEYBERG, G</creatorcontrib><creatorcontrib>SOLOMAYER, Ef</creatorcontrib><creatorcontrib>KUREK, R</creatorcontrib><creatorcontrib>WALLWIENER, D</creatorcontrib><creatorcontrib>GEBAUER, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FEHM, T</au><au>JÄGER, W</au><au>KRAEMER, S</au><au>SOHN, C</au><au>SOLOMAYER-MEYBERG, G</au><au>SOLOMAYER, Ef</au><au>KUREK, R</au><au>WALLWIENER, D</au><au>GEBAUER, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes of Serum HER2 Status during Clinical Course of Metastatic Breast Cancer Patients</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>24</volume><issue>6</issue><spage>4205</spage><epage>4210</epage><pages>4205-4210</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: Serum HER2 testing allows the determination of the real-time HER2 status of breast cancer patients. The aim of
this investigation was to study (i) whether changes of serum HER2 status occur during the clinical course of breast cancer
and (ii) to evaluate the prognostic significance of serum HER2 status, at the time of first diagnosis of primary breast cancer
and at the onset of metastatic disease, for survival after relapse (SAR). Materials and Methods: HER2 serum levels were retrospectively
measured in 152 breast cancer patients at the time of first diagnosis of breast cancer and at the onset of metastatic disease
by enzyme immunoassay. Results: Twenty-seven out of 152 (18%) patients had elevated HER2 serum levels at the time of first
diagnosis of breast cancer. In contrast, 56 out of 152 (37%) patients showed elevated serum HER2 levels when metastases were
diagnosed. A change of serum HER2 status during clinical course was observed in 43 out of 152 (28%) patients. Serum HER2 status
at the time of first diagnosis of breast cancer had no impact on survival after relapse (SAR) (p=0.4). However, the median
SAR for serum HER2-positive patients at the onset of metastatic disease was significantly shorter (8 months, 95% CI: 3-12)
compared to patients serum HER2-negative at this time (18 months, 95% CI: 14-22) (p<0.01). Conclusion: Serum HER2 status can
change during the course of disease. Therefore, the serum HER2 status should be re-evaluated at the time of diagnosis of metastatic
disease to optimize treatment decisions.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>15739264</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2004-11, Vol.24 (6), p.4205-4210 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67251797 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Biological and medical sciences Breast Neoplasms - blood Breast Neoplasms - pathology Female Gynecology. Andrology. Obstetrics Humans Mammary gland diseases Medical sciences Neoplasm Metastasis Receptor, ErbB-2 - blood Retrospective Studies Tumors |
| title | Changes of Serum HER2 Status during Clinical Course of Metastatic Breast Cancer Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T22%3A04%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20of%20Serum%20HER2%20Status%20during%20Clinical%20Course%20of%20Metastatic%20Breast%20Cancer%20Patients&rft.jtitle=Anticancer%20research&rft.au=FEHM,%20T&rft.date=2004-11-01&rft.volume=24&rft.issue=6&rft.spage=4205&rft.epage=4210&rft.pages=4205-4210&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E67251797%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67251797&rft_id=info:pmid/15739264&rfr_iscdi=true |